Genprex Reports Positive Interim Data from Oncoprex, Tarceva Combo Trial in Advanced NSCLC
News
Genprex announced that its immunogene therapy candidate Oncoprex in combination with Genentech’s Tarceva (erlotinib) demonstrated positive Phase 2 interim trial results in patients with late-stage non-small cell lung cancer (NSCLC). The ... Read more